How to buy Catalent shares

Own Catalent shares in just a few minutes.

catalent logo

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Catalent, Inc (CTLT) is a leading drug manufacturers-specialty & generic business with stocks listed in the US. It opened the day at US$108.47 after a previous close of US$108.47. During the day the price has varied from a low of USD107.815 to a high of USD109.33. The latest price was USD108.83 (25 minute delay). Catalent is listed on the NYSE. All prices are listed in US Dollars.

How to buy shares in Catalent

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Catalent. Find the share by name or ticker symbol: CTLT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Catalent reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$100.61, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Catalent, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Catalent. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Catalent share price

Use our graph to track the performance of CTLT stocks over time.

Catalent shares at a glance

Information last updated 2021-06-16.
Previous closeUS$108.47
Change US$0.36
Change % 0.3319%
Volume 132,695
Information last updated 2021-06-17.
52-week rangeUS$69.52 - US$127.68
50-day moving average US$105.0824
200-day moving average US$107.6273
Target priceUS$134.7
PE ratio 36.5019
Dividend yield N/A (0%)
Earnings per share (TTM) US$2.953

Compare share trading platforms to buy stock

Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro (US, EU stock trading)
US$10 per month if there’s been no login for 12 months
Global shares, US shares, ETFs
Zero brokerage share trading on US stocks with trades as low as $50.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
$50 per quarter if you make fewer than three trades in that period
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Saxo Capital Markets (Classic account)
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Acess 19,000+ stocks on 37 exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Stockbroking
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Catalent stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Catalent price performance over time

Historical closes compared with the last close of $108.83

1 week (2021-06-17) -1.56%
1 month (2021-05-24) 6.11%
3 months (2021-03-23) 1.33%
6 months (2020-12-23) 3.79%
1 year (2020-06-23) 52.49%
2 years (2019-06-21) 104.41%
3 years (2018-06-22) 161.99%
5 years (2016-06-23) 359.97%

Is Catalent under- or over-valued?

Valuing Catalent stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalent's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Catalent's P/E ratio

Catalent's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 37x. In other words, Catalent shares trade at around 37x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Catalent's PEG ratio

Catalent's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.2624. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Catalent's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Catalent's EBITDA

Catalent's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$875.8 million.

The EBITDA is a measure of a Catalent's overall financial performance and is widely used to measure a its profitability.

Catalent financials

Revenue TTM US$3.8 billion
Operating margin TTM 15.79%
Gross profit TTM US$983.3 million
Return on assets TTM 4.68%
Return on equity TTM 16.22%
Profit margin 14.82%
Book value 21.804
Market capitalisation US$18.4 billion

TTM: trailing 12 months

Shorting Catalent shares

There are currently 2.4 million Catalent shares held short by investors – that's known as Catalent's "short interest". This figure is 5.5% up from 2.3 million last month.

There are a few different ways that this level of interest in shorting Catalent shares can be evaluated.

Catalent's "short interest ratio" (SIR)

Catalent's "short interest ratio" (SIR) is the quantity of Catalent shares currently shorted divided by the average quantity of Catalent shares traded daily (recently around 1.1 million). Catalent's SIR currently stands at 2.13. In other words for every 100,000 Catalent shares traded daily on the market, roughly 2130 shares are currently held short.

However Catalent's short interest can also be evaluated against the total number of Catalent shares, or, against the total number of tradable Catalent shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Catalent's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Catalent shares in existence, roughly 10 shares are currently held short) or 0.0141% of the tradable shares (for every 100,000 tradable Catalent shares, roughly 14 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Catalent.

Find out more about how you can short Catalent stock.

Catalent share dividends

We're not expecting Catalent to pay a dividend over the next 12 months.

Catalent share price volatility

Over the last 12 months, Catalent's shares have ranged in value from as little as US$69.52 up to US$127.68. A popular way to gauge a stock's volatility is its "beta".

CTLT.US volatility(beta: 1.45)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Catalent's is 1.4505. This would suggest that Catalent's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Catalent overview

Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; Arcturus Therapeutics Holdings Inc.; and BrainStorm Cell Therapeutics Inc. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site
Not sure what platform to go with?
Take this quick quiz to find the right share trading platform